Solid-phase total synthesis of (-)-apratoxin A and its analogues and their biological evaluation. 2011

Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aza-Aoba, Aramaki, Aoba, Sendai 980-8578, Japan. doi_taka@mail.pharm.tohoku.ac.jp

Two approaches for the solid-phase total synthesis of apratoxin A and its derivatives were accomplished. In synthetic route A, the peptide was prepared by the sequential coupling of the corresponding amino acids on trityl chloride SynPhase Lanterns. After cleavage from the polymer-support, macrolactamization of 10, followed by thiazoline formation, provided apratoxin A. This approach, however, resulted in low yield because the chemoselectivity was not sufficient for the formation of the thiazoline ring though its analogue 33 was obtained. However, in synthetic route B, a cyclization precursor was prepared by solid-phase peptide synthesis by using amino acids 13-15 and 18. The final macrolactamization was performed in solution to provide apratoxin A in high overall yield. This method was then successfully applied to the synthesis of apratoxin analogues. The cytotoxic activity of the synthetic derivatives was then evaluated. The epimer 34 was as potent as apratoxin A, and O-methyl tyrosine can be replaced by 7-azidoheptyl tyrosine without loss of activity. The 1,3-dipolar cycloaddition of 38 with phenylacetylene was performed in the presence of a copper catalyst without affecting the thiazoline ring.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047630 Depsipeptides Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized. Cyclic Depsipeptide,Cyclodepsipeptide,Depsipeptide,Peptolide,Peptolides,Cryptophycins,Cyclodepsipeptides,Depsipeptides, Cyclic,Cyclic Depsipeptides,Depsipeptide, Cyclic
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
October 2006, Chemistry (Weinheim an der Bergstrasse, Germany),
Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
January 2023, Organic letters,
Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
January 2020, Frontiers in chemistry,
Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
January 2012, The Journal of organic chemistry,
Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
April 2018, Angewandte Chemie (International ed. in English),
Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
November 2009, Chemistry (Weinheim an der Bergstrasse, Germany),
Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
December 2015, Chemistry (Weinheim an der Bergstrasse, Germany),
Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
January 2009, Advances in experimental medicine and biology,
Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
November 2000, Journal of medicinal chemistry,
Takayuki Doi, and Yoshitaka Numajiri, and Takashi Takahashi, and Motoki Takagi, and Kazuo Shin-ya
April 2013, Chemistry (Weinheim an der Bergstrasse, Germany),
Copied contents to your clipboard!